Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/62115
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- INI - Artigos de Periódicos [3460]
Metadata
Mostrar registro completo
CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HUMAN IMMUNODEFICIENCY VIRUS–UNINFECTED INDIVIDUALS IN HPTN 077
Autor(es)
Landovitz, Raphael J.
Zangeneh, Sahar Z.
Chau, Gordon
Grinsztejn, Beatriz
Eron, Joseph J.
Dawood, Halima
Magnus, Manya
Liu, Albert Y.
Panchia, Ravindre
Hosseinipour, Mina C.
Kofron, Ryan
Margolis, David A.
Rinehart, Alex
Adeyeye, Adeola
Burns, David
McCauley, Marybeth
Cohen, Myron S.
Currier, Judith S.
Zangeneh, Sahar Z.
Chau, Gordon
Grinsztejn, Beatriz
Eron, Joseph J.
Dawood, Halima
Magnus, Manya
Liu, Albert Y.
Panchia, Ravindre
Hosseinipour, Mina C.
Kofron, Ryan
Margolis, David A.
Rinehart, Alex
Adeyeye, Adeola
Burns, David
McCauley, Marybeth
Cohen, Myron S.
Currier, Judith S.
Afiliação
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de HIV. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of KwaZulu-Natal. Department of Medicine. Pietermaritzburg, Durban, South Africa.
George Washington University. Milken Institute School of Public Health. Department of Epidemiology and Biostatistics. Washington, DC, USA.
San Francisco Department of Public Health. Population Health Division. Bridge HIV. California, USA.
University of the Witwatersrand. Chris Hani Baragwanath Academic Hospital. Perinatal HIV Research Unit. Soweto, South Africa.
University of North Carolina. Chapel Hill School of Medicine. Division of Infectious Diseases. North Carolina, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
Science Facilitation Department. Washington DC, USA.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de HIV. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of KwaZulu-Natal. Department of Medicine. Pietermaritzburg, Durban, South Africa.
George Washington University. Milken Institute School of Public Health. Department of Epidemiology and Biostatistics. Washington, DC, USA.
San Francisco Department of Public Health. Population Health Division. Bridge HIV. California, USA.
University of the Witwatersrand. Chris Hani Baragwanath Academic Hospital. Perinatal HIV Research Unit. Soweto, South Africa.
University of North Carolina. Chapel Hill School of Medicine. Division of Infectious Diseases. North Carolina, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
Science Facilitation Department. Washington DC, USA.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
Resumo em Inglês
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Compartilhar